awmsg logo



selexipag (Uptravi®)


Reference No. 700


Appraisal information

selexipag (Uptravi®) 200 µg film-coated tablet
selexipag (Uptravi®) 400 µg film-coated tablet
selexipag (Uptravi®) 600 µg film-coated tablet
selexipag (Uptravi®) 800 µg film-coated tablet
selexipag (Uptravi®) 1000 µg film-coated tablet
selexipag (Uptravi®) 1200 µg film-coated tablet
selexipag (Uptravi®) 1400 µg film-coated tablet
selexipag (Uptravi®) 1600 µg film-coated tablet


Company: Actelion Pharmaceuticals UK Ltd
BNF category: Cardiovascular system
NMG meeting date: 07/02/2018
AWMSG meeting date: Not scheduled
   
   
Submission Type: Full Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE‑5) inhibitor, or as monotherapy in patients who are not candidates for these therapies
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinician and Patient Involvement Group (CAPIG) Meeting Summary
Download